{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:07:30Z","timestamp":1774613250449,"version":"3.50.1"},"reference-count":29,"publisher":"Instituto Nacional de Salud (Colombia)","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["revistabiomedica.org"],"crossmark-restriction":false},"short-container-title":["Biomed."],"abstract":"<jats:p>Introduction. A second hematopoietic stem cell transplant is required when the first transplant fails, usually due to relapse or graft failure, and is associated with increased morbidity and mortality. Survival rates range from 74 to 82% in non-neoplastic diseases and from 39 to 58% in neoplastic conditions. Evidence on second hematopoietic stem cell transplant in children is limited, particularly in low- and middle-income countries.Objective. To describe the clinical characteristics, complications, and outcomes of children who underwent a second transplant at a high-complexity center between 2012 and 2024. Materials and methods. Case series study with descriptive and survival analysis using the Kaplan-Meier method in Stata 14\u2122.Results. A total of 346 allogeneic transplants were performed, of which 20 patients underwent a second transplant. Of these, 17 received a haploidentical donor for their second transplant, and the primary indication was a neoplastic disease in 13 cases. The second transplant was performed due to graft failure in 11 of the 20 patients, and due to relapse in the remaining 9. The mean age was 10.7 \u00b1 5 years, with a male predominance (14 out of 20). Haploidentical transplants accounted for 16 of the 20 cases, and 11 used the same donor. The most common complications were acute graft-versus-host disease in 7 cases, 2 of grade III, cytomegalovirus infection in 10 cases, and graft failure after the second transplant in 4 cases: 3 primary, 1 secondary. Transplant-related mortality was 31%. The 2-year overall survival was 54%, with a median follow-up of 11 months.Conclusions. Second hematopoietic stem cell transplant is a viable therapeutic option when no other alternatives are available, particularly in resource-limited settings.<\/jats:p>","DOI":"10.7705\/biomedica.7946","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:30:47Z","timestamp":1772807447000},"page":"121-217","update-policy":"https:\/\/doi.org\/10.7705\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Second allogeneic transplants in children: twelve years of experience","Segundos trasplantes alog\u00e9nicos en ni\u00f1os: experiencia de doce a\u00f1os"],"prefix":"10.7705","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3173-6059","authenticated-orcid":false,"given":"Alexis Antonio","family":"Franco","sequence":"first","affiliation":[{"name":"Unidad de Trasplante de M\u00e9dula \u00d3sea, Servicio de Hemato-Oncolog\u00eda Pedi\u00e1trica, Departamento Materno-Infantil, Fundaci\u00f3n Valle del Lili, Cali, Colombia; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5577-970X","authenticated-orcid":false,"given":"Eliana","family":"Manzi Tarapues","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia;\u00a0Centro de Investigaciones Cl\u00ednicas, Fundaci\u00f3n Valle del Lili, Cali, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0555-6521","authenticated-orcid":false,"given":"Sergio Camilo","family":"Cabrera Salcedo","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Cl\u00ednicas, Fundaci\u00f3n Valle del Lili, Cali, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0664-9252","authenticated-orcid":false,"given":"Diana Marcela","family":"Mu\u00f1oz Caluce","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Cl\u00ednicas, Fundaci\u00f3n Valle del Lili, Cali, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1465-7957","authenticated-orcid":false,"given":"Diego","family":"Medina","sequence":"additional","affiliation":[{"name":"Unidad de Trasplante de M\u00e9dula \u00d3sea, Servicio de Hemato-Oncolog\u00eda Pedi\u00e1trica, Departamento Materno-Infantil, Fundaci\u00f3n Valle del Lili, Cali, Colombia; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4444","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"159168","doi-asserted-by":"crossref","unstructured":"Fraint E, Holuba MJ, Wray L. Pediatric hematopoietic stem cell transplant. Pediatr Rev. 2020;41:609-11. https:\/\/doi.org\/10.1542\/pir.2020-0130","DOI":"10.1542\/pir.2020-0130"},{"key":"159169","doi-asserted-by":"crossref","unstructured":"Morton LM, Saber W, Baker KS, Barrett AJ, Bhatia S, Engels EA, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biol Blood Marrow Transplant. 2017;23:367-78. https:\/\/doi.org\/10.1016\/j.bbmt.2016.09.005","DOI":"10.1016\/j.bbmt.2016.09.005"},{"key":"159170","doi-asserted-by":"crossref","unstructured":"Laberko A, Sultanova E, Idarmacheva A, Skvortsova Y, Shelikhova L, Nechesnyuk A, et al. Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity. Bone Marrow Transplant. 2023;58:273-81. https:\/\/doi.org\/10.1038\/s41409-022-01883-4","DOI":"10.1038\/s41409-022-01883-4"},{"key":"159171","doi-asserted-by":"crossref","unstructured":"Parikh SH, Satwani P, Ahn KW, Sahr NA, Fretham C, Abraham AA, et al. Survival trends in infants undergoing allogeneic hematopoietic cell transplant. JAMA Pediatr. 2019;173:e190081. https:\/\/doi.org\/10.1001\/jamapediatrics.2019.0081","DOI":"10.1001\/jamapediatrics.2019.0081"},{"key":"159172","doi-asserted-by":"crossref","unstructured":"Kudo K, Muramatsu H, Yoshida N, Kobayashi R, Yabe H, Tabuchi K, et al. Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia. Bone Marrow Transplant. 2015;50:1312-5. https:\/\/doi.org\/10.1038\/bmt.2015.153","DOI":"10.1038\/bmt.2015.153"},{"key":"159173","doi-asserted-by":"crossref","unstructured":"Lu Y, Zhang JP, Zhao YL, Xiong M, Sun RJ, Cao XY, et al. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study. Front Immunol. 2023;13:1066748. https:\/\/doi.org\/10.3389\/fimmu.2022.1066748","DOI":"10.3389\/fimmu.2022.1066748"},{"key":"159174","doi-asserted-by":"crossref","unstructured":"Yi ES, Ju HY, Lee JW, Sung KW, Hur J, Yoo KH. second allogeneic hematopoietic cell transplantation following graft failure in children. J Korean Med Sci. 2025;40:e48. https:\/\/doi.org\/10.3346\/jkms.2025.40.e48","DOI":"10.3346\/jkms.2025.40.e48"},{"key":"159175","doi-asserted-by":"crossref","unstructured":"Kedmi M, Resnick IB, Dray L, Aker M, Samuel S, Gesundheit B, et al. A retrospective review of the outcome after second or subsequent allogeneic transplantation. Biol Blood Marrow Transplant. 2009;15:483-9. https:\/\/doi.org\/10.1016\/j.bbmt.2009.01.009","DOI":"10.1016\/j.bbmt.2009.01.009"},{"key":"159176","doi-asserted-by":"crossref","unstructured":"Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, et al. Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: A Retrospective Cohort on Behalf of the Grupo Espa\u00f1ol de Trasplante Hematopoyetico. Biol Blood Marrow Transplant. 2016;22:584-8. https:\/\/doi.org\/10.1016\/j.bbmt.2015.11.012","DOI":"10.1016\/j.bbmt.2015.11.012"},{"key":"159177","doi-asserted-by":"crossref","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, Kr\u00f6ger N, Zeiser R, et al. How risky is a second allogeneic stem cell transplantation? Leukemia. 2024;38:1799-807. https:\/\/doi.org\/10.1038\/s41375-024-02318-3","DOI":"10.1038\/s41375-024-02318-3"},{"key":"159178","doi-asserted-by":"crossref","unstructured":"Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J, et al. Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. Bone Marrow Transplant. 2016;51:186-93. https:\/\/doi.org\/10.1038\/bmt.2015.221","DOI":"10.1038\/bmt.2015.221"},{"key":"159179","doi-asserted-by":"crossref","unstructured":"Lund TC, Ahn KW, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, et al. Outcomes after second hematopoietic cell transplantation in children and young adults with relapsed acute leukemia. Biol Blood Marrow Transplant. 2019;25:301-6. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.016","DOI":"10.1016\/j.bbmt.2018.09.016"},{"key":"159180","doi-asserted-by":"crossref","unstructured":"Aljasem HA, Messner HA, Lipton JH, Kim DDH, Viswabandya A, Thyagu S, et al. Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience. Eur J Haematol. 2018;100:308-14. https:\/\/doi.org\/10.1111\/ejh.13015","DOI":"10.1111\/ejh.13015"},{"key":"159181","doi-asserted-by":"crossref","unstructured":"Yaniv I, Krauss AC, Beohou E, Dalissier A, Corbacioglu S, Zecca M, et al. Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: A retrospective EBMT-PDWP Study. Biol Blood Marrow Transplant. 2018;24:1629-42. https:\/\/doi.org\/10.1016\/j.bbmt.2018.03.002","DOI":"10.1016\/j.bbmt.2018.03.002"},{"key":"159182","doi-asserted-by":"crossref","unstructured":"Rostami T, Rostami MR, Mirhosseini AH, Mohammadi S, Nikbakht M, Alemi H, et al. Graft failure after allogeneic hematopoietic stem cell transplantation in pediatric patients with acute leukemia: autologous reconstitution or second transplant? Stem Cell Res Ther. 2024;15:111. https:\/\/doi.org\/10.1186\/s13287-024-03726-z","DOI":"10.1186\/s13287-024-03726-z"},{"key":"159183","doi-asserted-by":"crossref","unstructured":"Sun YQ, Wang Y, Wang FR, Yan CH, Cheng YF, Chen YH, et al. Graft failure in patients with hematological malignancies: a successful salvage with a second transplantation from a different haploidentical donor. Front Med. 2021;8:604085. https:\/\/doi.org\/10.3389\/fmed.2021.604085","DOI":"10.3389\/fmed.2021.604085"},{"key":"159184","unstructured":"Zhao YQ, Song YZ, Li ZH, Yang F, Xu T, Li FF, et al. Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant. Zhonghua Xue Ye Xue Za Zhi. 2023;44:465-71. https:\/\/doi:10.3760\/cma.j.issn.0253-2727.2023.06.004"},{"key":"159185","doi-asserted-by":"crossref","unstructured":"Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, et al. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2015;21:151-8. https:\/\/doi.org\/10.1016\/j.bbmt.2014.10.006","DOI":"10.1016\/j.bbmt.2014.10.006"},{"key":"159186","doi-asserted-by":"crossref","unstructured":"Corbacioglu S, Mooyaart J, Polge E, Boreland W, Lemaitre J, Peczynski C, et al. Graft versus-host disease (GvHD) and steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation: a large real-world EBMT-based epidemiology and treatment pattern study. Blood. 2023;142(Suppl 1):7016. https:\/\/doi.org\/10.1182\/blood-2023-177866","DOI":"10.1182\/blood-2023-177866"},{"key":"159187","doi-asserted-by":"crossref","unstructured":"Vinci L, Flotho C, Noellke P, Lebrecht D, Masetti R, de Haas V, et al. Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft. Bone Marrow Transplant. 2023;58:607-9. https:\/\/doi.org\/10.1038\/s41409-023-01942-4","DOI":"10.1038\/s41409-023-01942-4"},{"key":"159188","doi-asserted-by":"crossref","unstructured":"Devillier R, F\u00fcrst S, El-Cheikh J, Castagna L, Harbi S, Granata A, et al. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:370-4. https:\/\/doi.org\/10.1016\/j.bbmt.2013.11.030","DOI":"10.1016\/j.bbmt.2013.11.030"},{"key":"159189","doi-asserted-by":"crossref","unstructured":"Harada K, Najima Y, Kato M, Fuji S, Shinohara A, Nakamae H, et al. Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2022;116:744-53. https:\/\/doi.org\/10.1007\/s12185-022-03405-w","DOI":"10.1007\/s12185-022-03405-w"},{"key":"159190","doi-asserted-by":"crossref","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628-33. https:\/\/doi.org\/10.1016\/j.bbmt.2009.07.004","DOI":"10.1016\/j.bbmt.2009.07.004"},{"key":"159191","doi-asserted-by":"crossref","unstructured":"Yamada M, Sakamoto K, Tomizawa D, Ishikawa Y, Matsui T, Gocho Y, et al. a prospective viral monitoring study after pediatric allogeneic hematopoietic stem cell transplantation for malignant and nonmalignant diseases. Transplant Cell Ther. 2021;27:872.e1-872.e8. https:\/\/doi.org\/10.1016\/j.jtct.2021.07.014","DOI":"10.1016\/j.jtct.2021.07.014"},{"key":"159192","doi-asserted-by":"crossref","unstructured":"Li Y, Oganisian A, Boge CLK, Hayes M, Newman A, Fisher BT, et al. 688. marginal structure models to estimate the effect of cytomegalovirus infection on hospitalization among children undergoing allogeneic hematopoietic cell transplantation. Open Forum Infect Dis. 2020;7(Suppl 1):S397-8. https:\/\/doi.org\/10.1093\/ofid\/ofaa439.880","DOI":"10.1093\/ofid\/ofaa439.880"},{"key":"159193","doi-asserted-by":"crossref","unstructured":"Ferreira AM, Moreira F, Guimaraes T, Spad\u00e3o F, Ramos JF, Batista MV, et al. Epidemiology, risk factors and outcomes of multi-drug-resistant bloodstream infections in haematopoietic stem cell transplant recipients: importance of previous gut colonization. J Hosp Infect. 2018;100:83-91. https:\/\/doi.org\/10.1016\/j.jhin.2018.03.004","DOI":"10.1016\/j.jhin.2018.03.004"},{"key":"159194","doi-asserted-by":"crossref","unstructured":"Zaj\u0105c-Spycha\u0142a O, Wachowiak J, Pieczonka A, Siewiera K, Fr\u0105czkiewicz J, Ka\u0142wak K, et al. Bacterial infections in pediatric hematopoietic stem cell transplantation recipients: incidence, epidemiology, and spectrum of pathogens: report of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation. Transpl Infect Dis. 2016;18:690-8. https:\/\/doi.org\/10.1111\/tid.12581","DOI":"10.1111\/tid.12581"},{"key":"159195","doi-asserted-by":"crossref","unstructured":"Ifversen M, Meisel R, Sedlacek P, Kalwak K, Sisinni L, Hutt D, et al. Supportive care during pediatric hematopoietic stem cell transplantation: prevention of infections. A report from workshops on supportive care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Front Pediatr. 2021;9:705179. https:\/\/doi.org\/10.3389\/fped.2021.705179","DOI":"10.3389\/fped.2021.705179"},{"key":"159196","doi-asserted-by":"crossref","unstructured":"Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143-238. https:\/\/doi.org\/10.1016\/j.bbmt.2009.06.019","DOI":"10.1016\/j.bbmt.2009.06.019"}],"container-title":["Biom\u00e9dica"],"original-title":[],"link":[{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/7946\/5842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/7946\/5842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:13:34Z","timestamp":1774610014000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/view\/7946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.7705\/biomedica.7946","relation":{},"ISSN":["2590-7379","0120-4157"],"issn-type":[{"value":"2590-7379","type":"electronic"},{"value":"0120-4157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"2026-03-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"Yes","order":0,"name":"peer_reviewed","label":"Peer Reviewed","group":{"name":"peer_review","label":"Peer Review"}},{"value":"Instituto Nacional de Salud","name":"publisher","label":"This article is maintained by"},{"value":"Biomedica","name":"journaltitle","label":"Journal Title"},{"value":"Art\u00edculos originales","name":"content_type","label":"Content Type"}]}}